To add, I would say acquisitions are probably also driven a lot by how compelling the asset/s are, and not just by time. Plenty of biotechs who have to do phase 3 trials alone, and then there are some biotechs who are snapped up after Phase I. CHM's assets are clearly interesting enough to bring established professionals into a tiny Australian biotech.
I feel lucky to be in this early. IMO
Ann: CDH17 CAR T PRECLINICAL DATA FEATURED IN NATURE CANCER, page-17
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.2¢ |
Change
0.002(20.0%) |
Mkt cap ! $11.70M | |||
| Open | High | Low | Value | Volume |
| 1.0¢ | 1.3¢ | 1.0¢ | $153.9K | 13.87M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 128195 | 1.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.2¢ | 1224999 | 4 |
View Market Depth
| Last trade - 16.10pm 05/11/2024 (20 minute delay) ? |
| CHM (ASX) Chart |